Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 12/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303320 | 0.90 | AVPR1B (0.81) | AVPR1B | |
| SCHEMBL4315024 | 0.89 | AVPR1B (0.84) | AVPR1B | |
| SCHEMBL8016622 | 0.86 | AVPR1B (0.54) | AVPR1BGRIN2BGRIN1NR1I2 | |
| SCHEMBL4302587 | 0.85 | AVPR1B (0.65) | AVPR1B | |
| SCHEMBL4302720 | 0.80 | AVPR1B (1.00) | AVPR1B | |
| SCHEMBL4305688 | 0.78 | AVPR1B (0.81) | AVPR1B | |
| SCHEMBL4311786 | 0.76 | AVPR1B (0.69) | AVPR1B | |
| SCHEMBL4307426 | 0.76 | AVPR1B (0.61) | AVPR1B | |
| Hydrochloric Acid SCHEMBL4312035 | 0.75 | AVPR1B (0.69) | AVPR1B | |
| SCHEMBL4315145 | 0.74 | AVPR1B (0.83) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |